FBXL5 depletion as a novel strategy against osteosarcoma: Evidence for MEK/ERK inhibition and enhanced therapeutic sensitivity
{{output}}
Osteosarcoma (OS) is the most common primary malignant bone tumor in adolescents. Despite standard treatments, including surgery and chemotherapy, the 5-year survival rate for metastatic OS remains
